The content on this site is intended for healthcare professionals only
Prof Thierry Facon speaks to ecancer in an online interview for the EHA 2021 virtual meeting about the MAIA study.
This study evaluated daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeolma, with the overall survival results being presented at this point. Initially, he talks about progression-free survival with regards to the drug combination used in this study.
Prof Facon further describes the results of this study in detail. In the end, he discusses the safety profile and efficacy of these drugs.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Relapsed refractory multiple myeloma
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
